Polycystic ovarian syndrome - Prognosis and treatment outcomes

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 6, 2007, Pages 529-535

  Hart, Roger ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

Androgens; Infertility; Metabolic syndrome; Metformin; Ovarian hyperstimulation syndrome; Polycystic ovarian syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CLOMIFENE CITRATE; DEXAMETHASONE; GLYCYRRHIZA EXTRACT; GONADOTROPIN; LETROZOLE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; ROSIGLITAZONE; SPIRONOLACTONE; TAMOXIFEN;

ACNE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET THERAPY; DOSE RESPONSE; DRUG INHIBITION; DRUG SAFETY; EXERCISE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LAPAROSCOPIC SURGERY; LONG TERM CARE; MACROSOMIA; MENSTRUAL IRREGULARITY; NONHUMAN; OBESITY; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPONTANEOUS ABORTION; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANOVULATION; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; CONTRACEPTIVES, ORAL; DIABETES MELLITUS; DIET; ESTROGEN ANTAGONISTS; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; METFORMIN; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS; TREATMENT OUTCOME;

EID: 36349001646     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f10e22     Document Type: Review

References (80)

1. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18:671-683.
2. European Society of Human Reproduction and Embryology/American Society of Reproductive Medicine. ESHRE/ASRM Rotterdam Consensus Meeting Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-47.
3. European Society of Human Reproduction and Embryology/American Society of Reproductive Medicine. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
4. Agrawal R, Sharma S, Bekir J, et al. Prevalence of polycystic ovaries and polycystic ovary syndrome in lesbian women compared with heterosexual women. Fertil Steril 2004; 82:1352-1357.
5. Hart R, Norman R. Polycystic ovarian syndrome - prognosis and outcomes. Best Pract Res Clin Obstet Gynaecol 2006; 20:751-778. This is a good review of the clinical management of PCOS.
6. De Zegher F, Ibanez L. Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril 2006; 86 (Suppl 1):S4-S5.
7. Ibanez L, De Zegher F. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod 2004; 19:1725-1727.
8. Sloboda DM, Hart R, Doherty DA, et al. Age at menarche: influences of prenatal and postnatal growth. J Clin Endocrinol Metab 2007; 92:46-50.
9. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002; 174:1-5.
10. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 2005; 11:357-374.
11. Robinson JE, Birch RA, Taylor JA, et al. In utero programming of sexually differentiated gonadotrophin releasing hormone (GnRH) secretion. Domest Anim Endocrinol 2002; 23:43-52.
12. Short RV. Sexual differentiation of the brain of the sheep: effects of prenatal implantation of androgen. Film: general discussion. Ciba Found Symp 1978; 62:257-269.
13. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005; 11:631-643.
14. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57:356-359.
15. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36:105-111.
16. Norman RJ, Noakes M, Wu R, et al. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004; 10:267-280.
17. Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003; 18:1928-1932.
18. Clark AM, Thornley B, Tomlinson L, et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13:1502-1505.
19. Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82:421-429.
20. van Hooff MH, Voorhorst FJ, Kaptein MB, et al. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. Hum Reprod 1999; 14:2223-2229.
21. van Hooff M, Voorhorst FJ, Kaptein M, et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at 18 years. Hum Reprod 2004; 19:383-392.
22. Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum Reprod 2004; 19:1039-1042.
23. Venturoli S, Porcu E, Fabbri R, et al. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 1995; 38:974-980.
24. Ibanez L, Valls C, Cabre S, De Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab 2004; 89:4716-4720.
25. Costello M, Shrestha B, Eden J, et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007; CD005552.
26. Ibanez L, de Zegher F. Flutamide-metformin plus ethinylestradiol- drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 2005; 90:39-43.
27. Trent M, Austin SB, Rich M, Gordon CM. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr 2005; 5:107-111.
28. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of noninsulin-dependent diabetes mellitus. Am J Med 1995; 98:33S-39S.
29. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57:505-513.
30. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165-169.
31. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141-146.
32. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006; 185:227-239.
33. Teede HJ, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 2006; 30:45-53.
34. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30:471-478.
35. Azziz R, Marin C, Hoq L, et al. Healthcare-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005; 90:4650-4658.
36. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18:737-754.
37. Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 2003; 188:1158-1160.
38. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004; 89:2756-2762.
39. Cibula D, HillM, Fanta M, et al. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? Hum Reprod 2001; 16:940-944.
40. Armanini D, Castello R, Scaroni C, et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol 2007; 131:61-67.
41. Dereli D, Dereli T, Bayraktar F, et al. Endocrine and metabolic effects of rosiglitazone in nonobese women with polycystic ovary disease. Endocr J 2005; 52:299-308.
42. Penna IA, Canella PR, Reis RM, et al. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod 2005; 20:2396-2401.
43. Gambineri A, Pelusi C, Vicennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26:883-896.
44. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 2003; 79:1358-1364.
45. Moran LJ, Brinkworth G, Noakes M, Norman RJ. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 2006; 12:569-578.
46. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444:881-887.
47. Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006; 21:80-89.
48. Moll E, Bossuyt PM, Korevaar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006; 332:1485. A multicentre, RCT of the effect of the addition of placebo or metformin to clomiphene citrate demonstrated that there is no additional benefit derived from the addition of metformin to clomiphene citrate.
49. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551-566. A multicentre, RCT, powered to determine an effect on live-birth rate, of clomiphene citrate and placebo, a combination of extended release metformin and placebo, or a combination of both active drugs, all discontinued on pregnancy confirmation, demonstrated a significantly greater live-birth rate and multiple pregnancy rate in the clomiphene citrate group.
50. Neveu N, Granger L, St-Michel P, Lavoie HB. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril 2007; 87:113-120. Retrospective study of the effect of clomiphene citrate or metformin alone, where patients were able to choose their own therapy, or combined therapy if anovulation persisted, demonstrated that ovulation was more consistent in the metformin group; however, pregnancy rates were no different across groups.
51. Beck JI, Boothroyd C, Proctor M, et al. Oral antioestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev 2005; 1:CD002249.
52. Elnashar A, Abdelmageed E, Fayed M, Sharaf M. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod 2006; 21:1805-1808.
53. Branigan EF, Estes MA. A randomized clinical trial of treatment of clomiphene citrate-resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment. Am J Obstet Gynecol 2003; 188:1424-1428; discussion 1429-1430.
54. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006; 21:1400-1407.
55. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study. Fertil Steril 2007; 87:202-206.
56. Mitwally MF, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. Fertil Steril 2005; 83:229-231.
57. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003; 18:1588-1597.
58. Bayar U, Basaran M, Kiran S, et al. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril 2006; 86:1447-1451.
59. Bayar U, Tanriverdi HA, Barut A, et al. Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertil Steril 2006; 85:1045-1048.
60. Balen AH, Platteau P, Andersen AN, et al. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. BJOG 2006; 113:1195-1202.
61. Hugues JN, Cedrin-Durnerin I, Howles CM, et al. The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHOGroup II anovulation: a prospective randomized multicentre study. Hum Reprod 2006; 21:2817-2822.
62. Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod 2006; 21:1387-1399. This paper is a very good review of the literature on metformin administration in IVF.
63. Farquhar C, Lilford R, Marjoribanks J, Vandekerckhove P. Laparoscopic 'drilling' by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2005; 2:CD001122.
64. Tabrizi NM, Mohammad K, Dabirashrafi H, et al. Comparison of 5-, 10-, and 15-point laparoscopic ovarian electrocauterization in patients with polycystic ovarian disease: a prospective, randomized study. JSLS 2005; 9:439-441.
65. National Institute for Clinical Excellence. Report on Fertility Assessment and Treatment for People with Fertility Problems. London: Department of Health; 2004.
66. Palomba S, Orio F Jr, Nardo LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:4801-4809.
67. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005; 84:611-616.
68. Heijnen EM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:13-21.
69. Tian L, Shen H, Lu Q, et al. Insulin resistance increases the risk of spontaneous abortion following assisted reproduction technology treatment. J Clin Endocrinol Metab 2007; 92:1430-1433.
70. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858-2864.
71. Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77:520-525.
72. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004; 19:1323-1330.
73. Khattab S, Mohsen IA, Foutouh IA, et al. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22:680-684.
74. Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673-683.
75. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006; 86:658-663.
76. Vanky E, Salvesen KA, Heimstad R, et al. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 2004; 19:1734-1740.
77. Checa MA, Requena A, Salvador C, et al. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update 2005; 11:375-390.
78. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; 2:CD003053.
79. Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54:1150-1156.
80. American Association of Clinical Endocrinologists. Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract 2005; 11:126-134.